Download
https://www.ndtvprofit.com/research-reports/biocon-q3-results-review-aggressive-capital-allocation-led-to-suppressed-return-ratios-axis-securities?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
The capital allocation on two fronts R&D, acqustion of Viatris has diluted return ratios to below ~10% despite growth in business.
Share